



33998-705 831 ST25.txt
SEQUENCE LISTING

<110> Nash, Norman
Scully, Audra
Gardell, Luis
Olsson, Roger
Gustafsson, Magnus

<120> USE OF LIPOXIN RECEPTOR, FPRL1, AS A TOOL FOR IDENTIFYING
COMPOUNDS EFFECTIVE IN THE TREATMENT OF PAIN AND INFLAMMATION

<130> 33998-705.831

<140> 10/590,001

<141> 2006-08-17

<150> PCT/US2004/036952

<151> 2004-11-04

<160> 2

<170> PatentIn version 3.3

<210> 1

<211> 2631

<212> DNA

<213> Human neutrophils and monocytes

<400> 1

```
ggcacgagga acaacctatt tgcaaagttg gcgcaaacat tcctgcctga caggaccatg      60
gacacagggt gtagagatag agatggctct ggctgtgcat tcagcagatt ctgtagatag      120
aattaatagg acttg gatg gattgtggtg agagaaagt aaatgaaaga taagttctag      180
tttggaagtt ttaacaactg aatgttttaa ctcaaataga cacaaaatat tggaagagt      240
gcaggtttgg gaggatgaga caatcaactg tttggttgag ccacgtagg tttgaaatgt      300
ctacgggatc ccgtggggag aggttatatc agactggagc accagagaga ggccaaggct      360
gatagtttag atgaaaagag agcatgatat ttaagccct gagactggat aatatcacct      420
atagaaagac tatatagaga taagagaggt ggggaacaag taaaagctgc gggacactcc      480
taaatttaga gtcaaattta gaggagaaaa tactagcaaa ggggactgaa aagcgggtggc      540
caattgagct tcaaatgcaa gtgaaagtgt gttgtgtgta catttatcat ctcatggcac      600
aggaaaaacg tgatttaagg agaaggaagc gatccaatgg gaagaagaga tccaatggat      660
cctctatcac gaagatattg agataagaac caatatggat ttgcaccac tgcatttgca      720
gccttgaggt cataagcatc ctgagaaaa tgcaccaggt gctgctggca agatggaaac      780
caacttctcc actcctctga atgaatatga agaagtgtcc tatgagtctg ctggctacac      840
tgttctgagg atcctcccat tgggtggtgct tggggtcacc tttgtcctcg gggtcctggg      900
caatgggctt gtgatctggg tggctggatt ccgatgaca cgcacagtca ccaccatctg      960
ttacctgaac ctggccctgg ctgacttttc tttcacggcc acattaccat tcctcattgt     1020
```

33998-705 831 ST25.txt

ctccatggcc atgggagaaa aatggccttt tggctggttc ctgtgtaagt taattcacat	1080
cgtggtggac atcaacctct ttggaagtgt cttcttgatt ggtttcattg cactggaccg	1140
ctgcatttgt gtcctgcac cagctctgggc ccagaaccac cgcactgtga gtctggccat	1200
gaaggtgatc gtcggacctt ggattcttgc tctagtcctt accttgccag ttttcctctt	1260
tttgactaca gtaactatta caaatgggga cacatcatgt actttcaact ttgcatcctg	1320
gggtggcacc cctgaggaga ggctgaaggt ggccattacc atgctgacag ccagagggat	1380
tatccggttt gtcattggct ttagcttgcc gatgtccatt gttgccatct gctatgggct	1440
cattgcagcc aagatccaca aaaagggcat gattaaatcc agccgtccct tacgggtcct	1500
cactgctgtg gtggcttctt tcttcacatg ttggtttccc tttcaactgg ttgcccttct	1560
gggcaccgtc tggctcaaag agatgttgtt ctatggcaag taaaaaatca ttgacatcct	1620
ggttaacca acgagctccc tggccttctt caacagctgc ctcaacccca tgctttacgt	1680
ctttgtgggc caagacttcc gagagagact gatccactcc ctgcccacca gtctggagag	1740
ggccctgtct gaggactcag cccaactaa tgacacggct gccaatctg cttcacctcc	1800
tgacagagact gagttacagg caatgtgagg atggggtcag ggatattttg agttctgttc	1860
atcctaccct aatgccagtt ccagcttcat ctacccttga gtcattattga ggcattcaag	1920
gatgcacagc tcaagtattt attcaggaaa aatgcttttg tgtccctgat ttggggctaa	1980
gaaatagaca gtcaggctac taaaatatta gtgttatttt ttgttttttg acttctgcct	2040
ataccctggg gtaagtggag ttgggaaata caagaagaga aagaccagtg gggatttgta	2100
agacttagat gagatagcgc ataataaggg gaagacttta aagtataaag taaaatgttt	2160
gctgtaggtt ttttatagct attaaaaaaa atcagattat ggaagttttc ttctattttt	2220
agtttgctaa gagttttctg tttctttttc ttacatcatg atgtgacttt gcattttatc	2280
aaatgcattt tctacatgta ttaagatggg catattattc ttcttctttt atgtaaatca	2340
ttataaataa tgttcattaa gttctgaatg ttaaactact cttgaattcc tggaataaac	2400
cacacttagt cctgatgtac tttaaattatt tatatctcac aggagttggg tagaatttct	2460
gtgtttatgt ttatatactg ttatttctact ttttctacta tccttgctaa gttttcatag	2520
aaaataagga acaaagagaa acttgtaatg gtctctgaaa aggaattgag aagtaattcc	2580
tctgattctg ttttctgggtg ttatatcttt attaaatatt cagaaaaatt c	2631

<210> 2
 <211> 351
 <212> PRT
 <213> Human neutrophils and monocytes

<400> 2

Met Glu Thr Asn Phe Ser Thr Pro Leu Asn Glu Tyr Glu Glu Val Ser
 Page 2

1 5 15
Tyr Glu Ser Ala Gly Tyr Thr Val Leu Arg Ile Leu Pro Leu Val Val
20 25 30
Leu Gly Val Thr Phe Val Leu Gly Val Leu Gly Asn Gly Leu Val Ile
35 40 45
Trp Val Ala Gly Phe Arg Met Thr Arg Thr Val Thr Thr Ile Cys Tyr
50 55 60
Leu Asn Leu Ala Leu Ala Asp Phe Ser Phe Thr Ala Thr Leu Pro Phe
65 70 75 80
Leu Ile Val Ser Met Ala Met Gly Glu Lys Trp Pro Phe Gly Trp Phe
85 90 95
Leu Cys Lys Leu Ile His Ile Val Val Asp Ile Asn Leu Phe Gly Ser
100 105 110
Val Phe Leu Ile Gly Phe Ile Ala Leu Asp Arg Cys Ile Cys Val Leu
115 120 125
His Pro Val Trp Ala Gln Asn His Arg Thr Val Ser Leu Ala Met Lys
130 135 140
Val Ile Val Gly Pro Trp Ile Leu Ala Leu Val Leu Thr Leu Pro Val
145 150 155 160
Phe Leu Phe Leu Thr Thr Val Thr Ile Pro Asn Gly Asp Thr Tyr Cys
165 170 175
Thr Phe Asn Phe Ala Ser Trp Gly Gly Thr Pro Glu Glu Arg Leu Lys
180 185 190
Val Ala Ile Thr Met Leu Thr Ala Arg Gly Ile Ile Arg Phe Val Ile
195 200 205
Gly Phe Ser Leu Pro Met Ser Ile Val Ala Ile Cys Tyr Gly Leu Ile
210 215 220
Ala Ala Lys Ile His Lys Lys Gly Met Ile Lys Ser Ser Arg Pro Leu
225 230 235 240
Arg Val Leu Thr Ala Val Val Ala Ser Phe Phe Ile Cys Trp Phe Pro
245 250 255

33998-705 831 ST25.txt

Phe Gln Leu Val Ala Leu Leu Gly Thr Val Trp Leu Lys Glu Met Leu
260 265 270

Phe Tyr Gly Lys Tyr Lys Ile Ile Asp Ile Leu Val Asn Pro Thr Ser
275 280 285

Ser Leu Ala Phe Phe Asn Ser Cys Leu Asn Pro Met Leu Tyr Val Phe
290 295 300

Val Gly Gln Asp Phe Arg Glu Arg Leu Ile His Ser Leu Pro Thr Ser
305 310 315 320

Leu Glu Arg Ala Leu Ser Glu Asp Ser Ala Pro Thr Asn Asp Thr Ala
325 330 335

Ala Asn Ser Ala Ser Pro Pro Ala Glu Thr Glu Leu Gln Ala Met
340 345 350